Efficacy, Immunogenicity and Cost Analysis of a Systematic Switch from Originator Infliximab to Biosimilar Ct-P13 of All Patients with Inflammatory Arthritis from a Single Center
AuthID
P-00S-AE7
P-00S-AE7